Sign In
|
Register
|
About Los Altos
|
Contact Us
Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast
|
Traffic
Los Altos News
Local News
Bay Area News
Business
Technology
Real Estate
Sports
High School Sports
Los Altos Gas Prices
Ski And Snow Reports
Financial Markets
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Museums
Family Fun
Arts & Culture
Parks
Annual Events
Accommodations
Hotel and Motel Management
Hotels & Resorts
Apartments
Art & Culture
Galleries & Dealers
Museums
Associations, Foundations and Organizations
Business & Professional Clubs
Civic, Social and Fraternal
Non-Profits
Professional & Trade Associations
Attractions & Entertainment
Amusement & Water Parks
Bowling, Billiards & Video Games
General Attractions
Golfing
Horseback Riding
Movie Theatres
Theatre
Automotive
Auto Rental
Dealers - New
Dealers - Used
Mobile Home Dealers
Motorcycles
Parts & Supplies
Radio & Alarm Systems
Repair & Service
Tires
Towing
Beauty & Fitness
Barbers
Beauty Salons
Cosmetics
Dance Clubs & Studios
Health Clubs & Gyms
Manicures
Nutrition
Skin Treatment
Yoga
Business & Professional Services
Appraisers
Building Maintenance & Janitorial
Business & Labor Organizations
Computer & Audio Visual Services
Consultants
Courier, Delivery & Messenger Service
Credit Check & Collection Agencies
Data Processing Service
Employment Services, Placement & Agencies
Engineer and Architect Services
Equipment & Supplies, Commercial & Industrial
Graphic Design & Art
Human Resource Services
Internet Services
Marketing & Advertising Services
Media Services
Notary Services
Photography
Printing & Publishing
Public Relations & Publicity
Security & Investigative Services
Shipping, Packaging & Postal Services
Signs & Banners
Staffing & Support Services
Translators & Interpreters
Contractors
Architects
Building Contractors & Consultants
Drywall, Plastering & Insulation
Electric
General Contractors
Heating, Cooling & AC
Landscaping
Painting & Wallcovering
Plumbing
Special Trade Contractors
Domestic Services
Child Care Services
Housecleaning
Pet Sitting and Day Care
Education
Colleges & Universities
Cont. Education
Elementary Schools
High Schools
Libraries
Preschools & Childcare
Private & Parochial
Public
Tutoring
Employment
Employment Agencies
Find or Post a Job
Temporary Help & Employment Contractors
Financial Services
Accountants & Tax
Banks & Credit Unions
Bookkeeping
Financial Brokers and Dealers
Financial Consultants
Financial Planning and Services
Investments
Loans
Mortgage Lenders
Golf
Government
Post Offices
State Government
Hair Salons
Health and Medicine
Alternative Medicine / Acupuncture
Chiropractors
Counseling
Dentistry
Dermatologists
Drug Stores & Pharmacies
Eye Care
Health Care Professionals
Home Health Care
Hospitals & Clinics
Medical Doctors
Medical Equipment & Supplies
Nutrition
Physical Therapist
Physicians & Surgeons
Social Services
Specialists - Health Care Professionals
Home & Garden
Appliances
Bed & Bath
Building Materials & Hardware
Cleaning Supplies & Services
Contractors
Domestic Services
Doors, Windows & Drapery
Floor Coverings
Furniture
Handyman
Home Improvement Centers
Interior Design & Decorating
Kitchen
Lamps & Lighting
Lawn & Garden
Locksmiths
Lumber
Nurseries & Garden Centers
Painting & Wallcoverings
Pest Control
Plumbing
Pools, Spas & Saunas
Safety & Security
Sewage & Septic Systems
Sprinklers
Insurance
Agents & Brokers
Health
Laser Hair Removal
Legal
Attorneys
Legal Services
Manufacturing & Industrial
Agriculture
Audio & Visual
Building Materials
Computers, Electronics & Telecommunications
Electronic Equipment
Food & Beverage
Industrial Supplies & Services
Machine Shops
Textiles & Apparel
Media
Radio Stations
Television Stations
Meeting & Event Planning
Event Facilities
Exhibit Designers
Meeting Planners
Party Rentals & Entertainment
Miscellaneous
Nightlife
Live Music
Personal Service
Child Care
Dry Cleaning and Laundry
Shoe Repair
Tailors and Alterations
Pets
Pet Grooming
Pet Supplies & Food - Retail
Veterinary Hospitals
Plastic Surgery
Aesthetic Surgeon
Plastic Surgeon
Real Estate
Appraisers
Assisted Living & Elder Care Service
Commercial
Developers
Property Management
Real Estate Agents and Brokers
Residential
Schools
Title Companies
Religion
Relocation
Storage
Restaurants
Bagels
Bakery
Barbecue
Coffee Houses
Continental
Deli
Fast Food
French
Ice Cream / Frozen Yogurt
Italian
Mexican
Pizza
Steaks, Chops
Sushi
Vietnamese
Wine
Shopping
Accessories
Antiques
Books
Cellular & Wireless
Children's and Infants Clothing
Clothing
Computer and Computer Software
Department Stores
Electronics
Flowers
Furniture
Gas Stations
Gifts & Specialty Shops
Grocery Stores
Health Food Stores
Home Improvement
Jewelry
Men's Clothing Stores
Pharmacies
Resale Shops
Shoe Stores
Shopping Centers & Malls
Smoke Shops
Sporting Goods
Thrift Stores
Toy Stores
Videos
Women's Clothing Stores
Spas
Day Spas
Resort Spas
Sports & Recreation
Arenas and Venues
Associations & Clubs
Equestrian
Golf Equipment & Supplies
Instruction
Martial Arts
Recreation Facilities
Skateboarding
Technology
Communications
Computer Services & Consultants
Internet Advertising & Services
Semiconductor
Software
Travel & Transportation
Airlines & Airports
Auto Rentals
Bus Lines & Charters
Taxi, Limousine & Shuttle
Tours & Excursions
Travel Agencies
Weddings
Cakes & Caterers
Your Business Here
Classifieds
Cars
Forums
Coupons
News Archives
Contests
Jobs
Search Hotels in Los Altos
CHECK-IN:
CHECK-OUT:
ROOMS:
1
2
3
4
Find A Business
or
Browse Listings
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Merck & Co., Inc.
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio
October 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma
October 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31
October 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
September 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
September 25, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus
September 24, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
September 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
September 18, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
September 15, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
September 14, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
September 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
September 11, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
September 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
September 03, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
August 29, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
August 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
August 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
August 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
August 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Second-Quarter 2024 Financial Results
July 30, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
July 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Fourth-Quarter 2024 Dividend
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Tickers
MRK
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
About Us
|
Contact Us
|
Privacy Policy
|
User Agreement
|
Advertise With Us
|
Site Map
Home
|
News
|
Travel
|
Restaurants
|
Nightlife
|
Things To Do
|
Shopping
|
Events
|
Directory
|
Real Estate
|
Blog
|
More
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.